Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma

(2018) Jing Huang et al.   CLINICAL CANCER RESEARCH

Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

(2018) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

(2017) Toshihiro Kudo et al.   LANCET ONCOLOGY

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

(2017) et al.   JAMA Oncology

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study

(2016) Jing Huang et al.   Journal of Thoracic Oncology

Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma

(2015) Xi Wang et al.   Thoracic Cancer

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

(2014) Susan J Dutton et al.   LANCET ONCOLOGY

S-1 Monotherapy as Second- or Third-Line Chemotherapy for Unresectable and Recurrent Esophageal Squamous Cell Carcinoma

(2013) Yasunori Akutsu et al.   ONCOLOGY

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

(2012) Jing Huang et al.   MEDICAL ONCOLOGY

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

(2011) Peter C. Thuss-Patience et al.   EUROPEAN JOURNAL OF CANCER

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy

(2011) Christiane Maria Rosina Thallinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Docetaxel and Cisplatin Chemotherapy in 5-Fluorouracil/Cisplatin Pretreated Esophageal Cancer

(2010) Hyun-Jeong Shim et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy

(2008) Alexandra Leary et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY